Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation
- PMID: 12098064
- DOI: 10.1038/sj.bmt.1703575
Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation
Abstract
Reduced CD34(+) cell viability due to cryopreservation has unknown effects on subsequent hematopoietic engraftment in autologous transplantation. Thirty-six consecutive autologous peripheral stem cell collections were analyzed for absolute viable CD34(+) cell numbers at the time of stem cell collection and prior to re-infusion. Viable CD34(+) cells were enumerated using single platform flow cytometry and the molecular exclusion dye 7-amino actinomycin D. The median number of viable CD34(+) cells was 3.6 x 10(6)/kg at the time of harvest and 2.0 x 10(6)/kg after thawing. When viable CD34(+)cells enumerated after thawing were <2.0, 2.0-5.0, or >5.0 x 10(6)/kg, the median time to platelet engraftment was 17, 12 and 10 days, respectively (P < 0.05 for comparison of the group with <2.0 x 10(6)/kg and the other two groups), and the median time to neutrophil engraftment was 13, 14 and 12 days, respectively (P = NS). A minimum of 2.0 x 10(6) CD34(+) cells/kg was harvested in 33 of 36 patients (92%) but only 19 of 36 (52%) patients met this threshold at the time of reinfusion. The reduced numbers of viable CD34(+) cells measured prior to re-infusion is associated with time to platelet engraftment and may be useful in monitoring stem cell loss during processing and identifying patients at risk of graft failure.
Similar articles
-
Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation.Vox Sang. 2008 Feb;94(2):146-52. doi: 10.1111/j.1423-0410.2007.01009.x. Epub 2007 Nov 19. Vox Sang. 2008. PMID: 18028260
-
Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.Biol Blood Marrow Transplant. 2009 Nov;15(11):1386-93. doi: 10.1016/j.bbmt.2009.06.018. Epub 2009 Aug 19. Biol Blood Marrow Transplant. 2009. PMID: 19822297
-
Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg.Cytotherapy. 2004;6(4):356-62. doi: 10.1080/14653240410004925. Cytotherapy. 2004. PMID: 16146888
-
Importance of CD34+ cell subsets in autologous PBSC transplantation: the mulhouse experience using CD34+CD38- cells as predictive tool for hematopoietic engraftment.J Biol Regul Homeost Agents. 2001 Jan-Mar;15(1):62-7. J Biol Regul Homeost Agents. 2001. PMID: 11388746 Review.
-
CD34+ CD90+ cells and late hematopoietic reconstitution after autologous peripheral blood stem cell transplantation.Leuk Lymphoma. 2004 Apr;45(4):661-8. doi: 10.1080/1042819031000140997. Leuk Lymphoma. 2004. PMID: 15160937 Review.
Cited by
-
Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.Bone Marrow Transplant. 2015 Jul;50(7):886-91. doi: 10.1038/bmt.2014.330. Epub 2015 Feb 9. Bone Marrow Transplant. 2015. PMID: 25665044 Review.
-
High-Throughput Cell Concentration Using A Piezoelectric Pump in Closed-Loop Viscoelastic Microfluidics.Micromachines (Basel). 2021 Jun 9;12(6):677. doi: 10.3390/mi12060677. Micromachines (Basel). 2021. PMID: 34207912 Free PMC article.
-
Microfluidic Sorting of Cells by Viability Based on Differences in Cell Stiffness.Sci Rep. 2017 May 17;7(1):1997. doi: 10.1038/s41598-017-01807-z. Sci Rep. 2017. PMID: 28515450 Free PMC article.
-
Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site.J Transl Med. 2021 Apr 8;19(1):145. doi: 10.1186/s12967-021-02810-9. J Transl Med. 2021. PMID: 33832504 Free PMC article.
-
Validation of long-term handling and storage conditions for hematopoietic stem cell products for autologous transplants.J Med Life. 2023 Apr;16(4):515-519. doi: 10.25122/jml-2022-0230. J Med Life. 2023. PMID: 37305819 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous